Patrik Gonçalves Jorge1, Maud Jaccard2, Kristoffer Petersson1, Maude Gondré2, Maria Teresa Durán2, Laurent Desorgher2, Jean-François Germond2, Philippe Liger3, Marie-Catherine Vozenin4, Jean Bourhis4, François Bochud2, Raphaël Moeckli2, Claude Bailat5. 1. Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland; Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland. 2. Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland. 3. PMB-Alcen, Peynier, France. 4. Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; Radio-Oncology Laboratory, DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland. 5. Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: Claude.bailat@chuv.ch.
Abstract
PURPOSE: Preclinical studies using a new treatment modality called FLASH Radiotherapy (FLASH-RT) need a two-phase procedure to ensure minimal uncertainties in the delivered dose. The first phase requires a new investigation of the reference dosimetry lying outside the conventional metrology framework from national metrology institutes but necessary to obtain traceability, repeatability, and stability of irradiations. The second consists of performing special quality assurance procedure prior to irradiation. MATERIALS AND METHODS: The Oriatron eRT6 (PMB-Alcen, France) is an experimental high dose-per-pulse linear accelerator, delivering a 6 MeV pulsed electron beam with mean dose-rates, ranging from a few Gy/min up to thousands of Gy/s. Absolute dosimetry is investigated with alanine, thermo-luminescent dosimeters (TLD) and radiochromic films as well as an ionization chamber for relative stability. The beam characteristic and dosimetry are prepared for three different setups. RESULTS: A cross-check between alanine, films and TLD revealed a dose agreement within 3% for dose-rates between 0.078 Gy/s and 1050 Gy/s, showing that these dosimeters are suitable for absolute dosimetry for FLASH-RT. In absence of appropriate setup dependent corrections, active dosimetry can reveal dose deviations up to 15% of the prescribed dose. These differences reduce to less than 3% when our dosimetric procedure is applied. CONCLUSION: We developed procedures to accurately irradiate biological models. Our method is based on validated absolute dosimeters and extends their use to routine FLASH irradiations. We reached an agreement of 3% between the delivered and prescribed dose and developed the requirements needed for workflows of preclinical and clinical studies.
PURPOSE: Preclinical studies using a new treatment modality called FLASH Radiotherapy (FLASH-RT) need a two-phase procedure to ensure minimal uncertainties in the delivered dose. The first phase requires a new investigation of the reference dosimetry lying outside the conventional metrology framework from national metrology institutes but necessary to obtain traceability, repeatability, and stability of irradiations. The second consists of performing special quality assurance procedure prior to irradiation. MATERIALS AND METHODS: The Oriatron eRT6 (PMB-Alcen, France) is an experimental high dose-per-pulse linear accelerator, delivering a 6 MeV pulsed electron beam with mean dose-rates, ranging from a few Gy/min up to thousands of Gy/s. Absolute dosimetry is investigated with alanine, thermo-luminescent dosimeters (TLD) and radiochromic films as well as an ionization chamber for relative stability. The beam characteristic and dosimetry are prepared for three different setups. RESULTS: A cross-check between alanine, films and TLD revealed a dose agreement within 3% for dose-rates between 0.078 Gy/s and 1050 Gy/s, showing that these dosimeters are suitable for absolute dosimetry for FLASH-RT. In absence of appropriate setup dependent corrections, active dosimetry can reveal dose deviations up to 15% of the prescribed dose. These differences reduce to less than 3% when our dosimetric procedure is applied. CONCLUSION: We developed procedures to accurately irradiate biological models. Our method is based on validated absolute dosimeters and extends their use to routine FLASH irradiations. We reached an agreement of 3% between the delivered and prescribed dose and developed the requirements needed for workflows of preclinical and clinical studies.
Authors: Barrett D Allen; Munjal M Acharya; Pierre Montay-Gruel; Patrik Goncalves Jorge; Claude Bailat; Benoît Petit; Marie-Catherine Vozenin; Charles Limoli Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841
Authors: Michele M Kim; Arash Darafsheh; Jan Schuemann; Ivana Dokic; Olle Lundh; Tianyu Zhao; José Ramos-Méndez; Lei Dong; Kristoffer Petersson Journal: IEEE Trans Radiat Plasma Med Sci Date: 2021-06-22
Authors: Emil Schüler; Munjal Acharya; Pierre Montay-Gruel; Billy W Loo; Marie-Catherine Vozenin; Peter G Maxim Journal: Med Phys Date: 2022-01-19 Impact factor: 4.506
Authors: Pierre Montay-Gruel; Mineh Markarian; Barrett D Allen; Jabra D Baddour; Erich Giedzinski; Patrik Goncalves Jorge; Benoît Petit; Claude Bailat; Marie-Catherine Vozenin; Charles Limoli; Munjal M Acharya Journal: Radiat Res Date: 2020-12-01 Impact factor: 2.841
Authors: Pierre Montay-Gruel; Munjal M Acharya; Charles L Limoli; Marie-Catherine Vozenin; Patrik Gonçalves Jorge; Benoît Petit; Ioannis G Petridis; Philippe Fuchs; Ron Leavitt; Kristoffer Petersson; Maude Gondré; Jonathan Ollivier; Raphael Moeckli; François Bochud; Claude Bailat; Jean Bourhis; Jean-François Germond Journal: Clin Cancer Res Date: 2020-10-15 Impact factor: 13.801
Authors: Igor Olaciregui-Ruiz; Sam Beddar; Peter Greer; Nuria Jornet; Boyd McCurdy; Gabriel Paiva-Fonseca; Ben Mijnheer; Frank Verhaegen Journal: Phys Imaging Radiat Oncol Date: 2020-08-29
Authors: Alexander Berne; Kristoffer Petersson; Iain D C Tullis; Robert G Newman; Borivoj Vojnovic Journal: Phys Med Biol Date: 2021-02-09 Impact factor: 3.609